# of Displayed Technologies: 1 / 1


Categories

Compound 13, an Mps1/TTK Kinase Inhibitor, for Triple Negative Breast Cancer Therapy
TS-037724 — Researchers at The Ohio State University have discovered Compound 13, a patent protected, orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple negative breast cancer upon daily administration.
Breast cancer is a heterogeneous group of tumors, which can be subdivided based on histopathological features, genetic alterations, and gene-expression profiles. Approximately 50-60% of all breast cancer patients and two-thirds of postmenopausal breast cancer patients have estrogen receptor positi…
  • College: College of Pharmacy
  • Inventors: Brueggemeier, Robert; Fisk, Harold; Li, Chenglong; Li, Pui-Kai "Tom"; Sugimoto, Yasuro
  • Licensing Officer: Schworer, Adam

Loading icon